Antimalarial drug discovery: screening of Brazilian medicinal plants and purified compounds

Background: Malaria is the most important parasitic disease and its control depends on specific chemotherapy, now complicated by Plasmodium falciparum that has become resistant to most commonly available antimalarials. Treatment of the disease requires quinine or drug combinations of artemisinin derivatives and other antimalarials. Further drug resistance is expected. New active compounds need to be discovered. Objective/method: To find new antimalarials from medicinal and randomly collected plants, crude extracts are screened against P. falciparum in cultures and in malaria animal models, following bioassays of purified fractions, and cytotoxicity tests. Conclusion: For antimalarial research, screening medicinal plants is more efficient than screening randomly chosen plants. Biomonitored fractionation allows selection of new active molecules identified as potential antimalarials in multidisciplinary projects in Brazil; no new molecule is available for human testing. The advantages of projects based on ethnopharmacology are discussed.     

Search for bioactive natural products from medicinal plants of Bangladesh

In our continuous search for bioactive natural products from natural resources, we explored medicinal plants of Bangladesh, targeting cancer-related tumor necrosis factor-related apoptosis-inducing ligand-signaling pathway, along with some other biological activities such as prostaglandin inhibitory activity, 1,1-diphenyl-2-picrylhydrazyl free-radical-scavenging activity, and cell growth inhibitory activity. Along with this, we describe a short field study on Sundarbans mangrove forests, Bangladesh, in the review.     

The use of marine-derived bioactive compounds as potential hepatoprotective agents

The marine environment may be explored as a rich source for novel drugs. A number of marine-derived compounds have been isolated and identified, and their therapeutic effects and pharmacological profiles are characterized. In the present review, we highlight the recent studies using marine compounds as potential hepatoprotective agents for the treatment of liver fibrotic diseases and discuss the proposed mechanisms of their activities. In addition, we discuss the significance of similar studies in Oman, where the rich marine life provides a potential for the isolation of novel natural, bioactive products that display therapeutic effects on liver diseases.     

Psoriasis drug discovery: methods for evaluation of potential drug candidates

INTRODUCTION: Psoriasis is a complex disease with several clinical subtypes, as well as variations in body location and severity. Many patients suffering from psoriasis now benefit from the increased understanding of the pathogenesis of the disease, which in turn drives translational efforts to test new therapeutic concepts in the clinic. However, a multitude of treatment options is currently needed to satisfy patient needs. AREAS COVERED: This review describes the drug discovery platform in relation to psoriasis with special emphasis on how the major disease mechanisms of psoriasis can be studied in experimental in vitro and in vivo settings. The value of using humanized models and experimental clinical studies is highlighted. EXPERT OPINION: The successful development of novel therapies requires a translational approach to develop and implement the best preclinical and experimental clinical models and analytical tools that capture the various biological aspects of the disease. There is a need for more advanced in vitro skin models that contain the relevant cellular constituents as well as a need for careful validation of relevant in vivo models for psoriasis.     

Preliminary screening the antioxidant potential of in vitro-propagated Amsonia orientalis: An example to sustainable use of rare medicinal plants in pharmaceutical studies

Amsonia orientalis (European Bluestar) is a critically endangered plant species with medicinal and ornamental properties. The rare availability of the species in nature limits its potential to be used for various purposes. However, plant tissue culture is an effective method for the cultivation of such vulnerable species without damaging their natural populations, which are very limited in nature for scientific purposes. By taking advantage of plant tissue culture, this study aimed to measure the phenolic substance and flavonoid contents in leaf extracts of in vitro-propagated Amsonia orientalis, and to investigate their antioxidant potentials through phosphomolybdate and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assays. The crude extracts prepared in water, aqueous ethanol, methanol, and acetone were tested. The highest phenolic substance content was found in the ethanolic extracts, while statistically the same flavonoid contents were found in the ethanolic, methanolic, and acetone extracts. Although the water extract had lesser flavonoid content, it exhibited a notable antioxidant property. The ethanolic leaf extract gave the highest antioxidant and DPPH radical scavenging activity, especially when used at 1 mg mL^?1 concentration. Also, the TLC fingerprint profile validated the presence of valuable phytoconstituents in the leaves of the plant. This study indicated that ultrasound-assisted extraction of minimal amounts of dried leaf samples from in vitro-propagated plants might be adequate for the pre-screening of the antioxidant capacity of rare plant species.     

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

Toxicity is a leading cause of attrition at all stages of the drug development process. The majority of safety-related attrition occurs preclinically, suggesting that approaches to identify 'predictable' preclinical safety liabilities earlier in the drug development process could lead to the design and/or selection of better drug candidates that have increased probabilities of becoming marketed drugs. In this Review, we discuss how the early application of preclinical safety assessment--both new molecular technologies as well as more established approaches such as standard repeat-dose rodent toxicology studies--can identify predictable safety issues earlier in the testing paradigm. The earlier identification of dose-limiting toxicities will provide chemists and toxicologists the opportunity to characterize the dose-limiting toxicities, determine structure-toxicity relationships and minimize or circumvent adverse safety liabilities.     

A survey of synthetic and natural phytotoxic compounds and phytoalexins as potential antimalarial compounds

The apicomplexan parasites pathogens such as Plasmodium spp. possess an apicoplast, a plastid organelle similar to those of plants. The apicoplast has some essential plant-like metabolic pathways and processes, making these parasites susceptible to inhibitors of these functions. The main objective of this paper is to determine if phytotoxins with plastid target sites are more likely to be good antiplasmodial compounds than are those with other modes of action. The antiplasmodial activities of some compounds with established phytotoxic action were determined in vitro on a chloroquine (CQ) sensitive (D6, Sierra Leone) strain of Plasmodium falciparum. In this study, we provide in vitro activities of almost 50 such compounds, as well as a few phytoalexins against P. falciparum. Endothall, anisomycin, and cerulenin had sufficient antiplasmodial action to be considered as new lead antimalarial structures. Some derivatives of fusicoccin possessed markedly improved antiplasmodial action than the parent compound. Our results suggest that phytotoxins with plastid targets may not necessarily be better antiplasmodials than those that act at other molecular sites. The herbicides, phytotoxins and the phytoalexins reported here with significant antiplasmodial activity may be useful probes for identification of new antimalarial drug targets and may also be used as new lead structures for new antiplasmodial drug discovery.     

Progress toward the discovery and development of efficacious BACE inhibitors

BACE (beta-site amyloid precursor protein [APP] cleavage enzyme) is a transmembrane aspartyl protease responsible for the first cleavage event in the processing of APP to Abeta peptide. Amyloid plaques composed of Abeta peptides are hypothesized to be the root cause of neuronal cell death in Alzheimer's disease patients. Thus, BACE has become a target of significant interest for pharmaceutical and academic research. The recent literature relating to the discovery and development of efficacious BACE inhibitors is reviewed with particular emphasis on the patent literature.     

A survey of the response of Korean medicinal plants on drug metabolism

Archives of Pharmacal Research - Alcohol extracts of plants widely used in the traditional medicine have been tested to establish if they affect the metabolism of drugs in mice. Fourteen of the...     

Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds

Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes. Electrophysiology is the most reliable in vitro screening method for identifying potential cardiac hERG liabilities, but only the recent advent of planar electrode-based voltage clamp electrophysiology promises sufficient throughput to support the drug testing needs of most drug discovery programs. We have assessed the reliability of this new format of the voltage clamp technology in measuring the activity of small molecules on the hERG channel. Based on the results herein of a screening against a panel of well-characterized hERG-active and -inactive molecules, we demonstrate that planar electrode electrophysiology, utilizing the Sealchip and PatchXpress technology platform (AVIVA Biosciences Corp., San Diego, CA), is comparable to traditional electrophysiology based on glass micropipettes in its reliability and data content. The new technology will allow significantly higher throughput and more thorough testing of pharmaceutical compounds.     

Using genetic findings in autism for the development of new pharmaceutical compounds

Rationale

The main reason for the current lack of effective treatments for the core symptoms of autism is our limited understanding of the biological mechanisms underlying this heterogeneous group of disorders. A primary value of genetic research is enhancing our insight into the biology of autism through the study of identified autism risk genes.

Objectives

In the current review we discuss (1) the genes and loci that are associated with autism, (2) how these provide us with essential cues as to what neurobiological mechanisms may be involved, and (3) how these mechanisms may be used as targets for novel treatments. Next, we provide an overview of currently ongoing clinical trials registered at clinicaltrials.gov with a variety of compounds. Finally, we review current approaches used to translate knowledge derived from gene discovery into novel pharmaceutical compounds and discuss their pitfalls and problems.

Conclusions

An increasing number of genetic variants associated with autism have been identified. This will generate new ideas about the biological mechanisms involved in autism, which in turn may provide new leads for the development of novel pharmaceutical compounds. To optimize this pipeline of drug discovery, large-scale international collaborations are needed for gene discovery, functional validation of risk genes, and improvement of clinical outcome measures and clinical trial methodology in autism.     

The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies

Introduction: In the past, clinical studies had demonstrated that aspirin and NSAIDs reduce the risk of colorectal cancer. After the discovery of selective prostaglandin-endoperoxide synthase 2 (PTGS2) inhibitors, the further beneficial effects of celecoxib and some other related structures (coxibs) have been demonstrated in both in vivo and in vitro studies.

Areas covered: The authors illustrate the role of prostaglandins following the overexpression of PTGS2 (COX-2) in signaling pathways. The authors elucidate the role of coxibs in cell proliferation, apoptosis, angiogenesis and multi-drug resistance and discuss the molecular mechanisms involved. The authors also present the strong evidence related to the usefulness of coxibs in several cancer cell lines.

Expert opinion: There have been a number of PTGS2 (COX-2) selective inhibitors suggested as potential anticancer therapies. In recent years, the development of nanotechnology has also had an impact on chemotherapy. Indeed, nanoparticles of cytotoxic drug carriers have demonstrated potential through their accumulation in cancer cells, and targeting these nanoparticles has been under evaluation. This area could be opened up for coxib development as they are potentially important targets in cancer cells. Further research using celecoxib as a co-drug with PTGS2-overexpressed and PTGS2-independent cancer is still needed.     

A further survey of the action of some medicinal plants on drug metabolism

Tabulated results are presented of a test for an activity affecting on drug metabolism of 75 plant samples frequently used in the traditional medicine in Korea.     

Medicinal plants as potential sources of lead compounds with anti-platelet and anti-coagulant activities

Medicinal plants are potential sources of lead compounds which can be further developed or optimised into novel therapeutics. This paper gives an overview of drug discovery from plants and an up-to-date and comprehensive review of plants and phytoconstituents reported to have anti-platelet and anti-coagulant activities.     

The potential medicinal value of plants from Asteraceae family with antioxidant defense enzymes as biological targets

Abstract

Context: Plants and most of the plant-derived compounds have long been known for their potential pharmaceutical effects. They are well known to play an important role in the treatment of several diseases from diabetes to various types of cancers. Today most of the clinically effective pharmaceuticals are developed from plant-derived ancestors in the history of medicine.

Objective: The aim of this study was to evaluate the free radical scavenging activity and total phenolic and flavonoid contents of methanol, ethanol, and acetone extracts from flowers and leaves of Onopordum acanthium L., Carduus acanthoides L., Cirsium arvense (L.) Scop., and Centaurea solstitialis L., all from the Asteraceae family, for investigating their potential medicinal values of biological targets that are participating in the antioxidant defense system such as catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx).

Materials and methods: In this study, free radical scavenging activity and total phenolic and flavonoid contents of the plant samples were assayed by DPPH, Folin–Ciocalteu, and aluminum chloride colorimetric methods. Also, the effects of extracts on CAT, GST, and GPx enzyme activities were investigated.

Results and discussion: The highest phenolic and flavonoid contents were detected in the acetone extract of C. acanthoides flowers, with 90.305?mg GAE/L and 185.43?mg Q/L values, respectively. The highest DPPH radical scavenging was observed with the methanol leaf extracts of C. arvense with an IC₅₀ value of 366?ng/mL. The maximum GPx and GST enzyme inhibition activities were observed with acetone extracts from the flower of C. solstitialis with IC₅₀ values of 79 and 232?ng/mL, respectively.     

An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment

Automated log P, pK(a), solubility, and chemical stability systems comprise an integrated process that provides early stage physicochemical property data to the discovery research organization. Capillary electrophoresis (CE) techniques are used to experimentally determine pK(a) and log P. Solubility is determined using a quasi-equilibrium approach employing sample quantitation by flow injection analysis with ultraviolet (UV) detection at 256 nm. Chemical stability is assessed by challenging compounds with pH 2, pH 7, pH 12, and 3% hydrogen peroxide solutions overnight, and comparing the chromatographic profiles of the stability challenged solutions to that of a freshly prepared control. Validation of the log P method using a set of drug-like compounds demonstrates that the method yields log P values within +/-0.5 units of literature values. The log P method is valid over the range -0.5-5.0, and the technique is compatible with acidic, neutral, and basic compounds. The pK(a) technique yields results within +/-0.2 units of corresponding values obtained by potentiometric titration over a pK(a) range of 2 to 12. Solubility is reported in a 3-60 microg/mL range, and the results are generally within 20% of values measured by equilibrium solubility techniques. The current level of automation supports the measurement of the physicochemical properties of 100 compounds per week. Physicochemical property data for approximately 2000 compounds have been generated to date.